Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Missouri for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Missouri only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Missouri (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Rachel Beggs (NPI 1831730357)

Field	Value
Entity Type	Individual
Organization	Rachel Beggs
Address	3600 Ne Ralph Powell Rd Ste B
City	Lees Summit
State	MO
ZIP	64064
Taxonomy	Nurse Practitioner
NPI Enumerated	October 6, 2019

Payer Source	Total Paid
Medicare	$1.4M
Medicaid	$0

Key Findings

This provider is effectively a single-payer Medicare practice: lifetime Medicare revenue is $1.4M and there is no Medicaid billing on file, so Medicaid does not contribute to this provider's reported revenue mix. That concentration means reimbursement exposure and growth are tied primarily to Medicare policies and beneficiary demand.

Revenue is highly concentrated in a small set of biologic injection codes: the precomputed top 3 Medicare codes account for 70.9% of the provider's total Medicare revenue, led by J3380 ($392.7K, 29.0%), J3245 ($286K, 21.1%), and J2357 ($281.7K, 20.8%). This concentration indicates that a handful of biologic therapies drive the majority of billed Medicare dollars.

The code mix signals an infusion/injectable biologics practice focused on specialty immunologic therapies: the top codes include J3380 (vedolizumab), J3245 (tildrakizumab), J2357 (omalizumab), J0517 (benralizumab), and J1569 (immune globulin), consistent with routine administration of high-cost biologics and in-clinic injection or infusion services. These products and services suggest clinical operations oriented toward ongoing maintenance dosing rather than episodic primary care encounters.

Competitive standing across top codes is mixed: for J3380 the provider ranks #51 of 620 nationally (92th percentile) but the dataset labels that usage as "typical, unremarkable volume for this code," indicating relatively strong placement yet not atypical practice patterns for that therapy. J2357 ranks #100 of 581 (83th percentile) and is also described as "typical, unremarkable volume," while J3245 ranks #157 of 225 (28th percentile) and is likewise labeled "typical, unremarkable volume," reflecting variation in market position by product.

Several administration and infusion CPT codes appear on the file, demonstrating in-office delivery capacity: 96365 ($10.8K), 96372 ($4.2K), 96366 ($2.3K), and 96413 ($13.4K) are present. Notably, 96372 (470 claims, $9 avg paid/claim, $4.2K revenue) is flagged as "notably above typical national volume," suggesting the provider gives an above-typical number of injectable procedures relative to peers even though these codes contribute only a small share of revenue.

There is modest participation in newer or lower-revenue specialty products: J1306 (inclisiran) appears with $35.8K revenue and ranks #419 of 462 (7th percentile), indicating limited use of that particular agent despite broader biologics activity. At the same time, supportive products like immune globulin (J1569, $125.8K, 9.3%) and benralizumab (J0517, $199.5K, 14.7%) represent secondary revenue contributors.

Operational and reimbursement risk is concentrated around high-cost biologics: because J3380, J3245, and J2357 together make up 70.9% of Medicare revenue, changes in coverage, pricing, or utilization management for these agents could materially affect top-line Medicare receipts. Inventory, buy-and-bill logistics, and payer contract terms for specialty injectables are likely key operational considerations for this provider.

The provider's NPI was enumerated on 2019-10-06 (~7 years ago), indicating a relatively recent practice tenure. Given the concentrated biologic-focused billing profile and the tenure, this may reflect a clinic or practitioner that established a specialty injection/infusion service in the last several years and has since built a Medicare revenue base around a small set of therapies.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

13 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J3380	Injection, vedolizumab, intravenous, 1 mg	23,100	$20	$392.7K
J3245	Injection, tildrakizumab, 1 mg	2,600	$110	$286K
J2357	Injection, omalizumab, 5 mg	9,390	$30	$281.7K
J0517	Injection, benralizumab, 1 mg	1,500	$130	$199.5K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	3,490	$40	$125.8K
J1306	Injection, inclisiran, 1 mg	3,980	$10	$35.8K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	170	$80	$13.4K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	280	$40	$10.8K
96372	A therapeutic, prophylactic, or diagnostic substance (a fluid, a drug, etc.) is injected via intramuscular or subcutaneous route into the patient's body. The procedure is performed by the physician…	470	$10	$4.2K
96366	The provider administers an intravenous infusion or infusions of a medication for an additional hour or subsequent hours after the first hour to prevent, treat, or diagnose a condition or disease.	180	$10	$2.3K

Showing 1–10 of 13

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 13 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Missouri Distribution

Rachel Beggs — 2 of 13 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Missouri

Full comparison — all codes billed, vs. state median

13 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J3245	5	10	4,100	$110	$475.4K
J3380	4	20	10,800	$20	$280.1K
J1569	9	10	4,350	$40	$171.2K
J0517	1	10	1,070	$130	$147.2K
J2357	2	10	3,300	$30	$128.1K
J1306	10	10	6,530	$10	$61.5K
96413	68	160	140	$100	$19.1K
96365	14	210	40	$50	$4.4K
96375	68	120	130	$10	$2.3K
96415	44	110	60	$20	$2.1K

Showing 1–10 of 13

Related Providers

Other providers that share a Tax Identification Number (TIN) with Rachel Beggs, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Patrick Jensen	MO	Family Nurse Practitioner	$1.8M	$0
Clare Roewe	KS	Family Nurse Practitioner	$952.9K	$0
Myranda Prather	KS	Family Nurse Practitioner	$692.8K	$0
Sarah Foster	MO	Family Nurse Practitioner	$675.5K	$0
Amy Carpenter	MO	Nurse Practitioner	$415.6K	$0
Robert Jackson	MO	Rheumatology Physician	$173.3K	$0
Breanna Muniz	KS	Family Nurse Practitioner	$153.2K	$0

Nearby Providers

Other providers in the same ZIP code as Rachel Beggs, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Michael Gowen	IL	Dermatology Physician	$768.6K	$4.8K
Bruce Fearon	MO	Family Medicine Physician	$725.1K	$0
Skin & Mohs Surgery Center, LLC	MO	Ambulatory Surgical Clinic/Center	$703.2K	$0
Sheldon Sebastian	MO	MOHS-Micrographic Surgery Physician	$636.7K	$0
Nicholas Golda	MO	MOHS-Micrographic Surgery Physician	$468.3K	$0
George Nahass	IL	Dermatopathology Physician	$378K	$1.2K
Midwest Digestive Health Center LLC	MO	Ambulatory Surgical Clinic/Center	$323.8K	$0
Lee Summit Asc Kc LLC	MO	Ambulatory Surgical Clinic/Center	$259.5K	$0
Theresa Mattingly	MO	Dermatology Physician	$205.9K	$0
Joseph Baker	MO	Family Medicine Physician	$205.2K	$0

Rachel Beggs — Billing Profile & Reimbursement Data

Sign up for Rachel Beggs — Billing Profile & Reimbursement Data policy alerts

Rachel Beggs — Billing Profile & Reimbursement Data

Sign up for Rachel Beggs — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References